-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, P41wmqnn4h/i/6jlDvZZtjuMLu051CvvHpi/pkmVUgGP+FLf8JTK38gQMAuxkJHF ueo8GjSDIjI+eulK7akaxA== 0001193125-08-063479.txt : 20080324 0001193125-08-063479.hdr.sgml : 20080324 20080324151707 ACCESSION NUMBER: 0001193125-08-063479 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 6 CONFORMED PERIOD OF REPORT: 20080324 FILED AS OF DATE: 20080324 DATE AS OF CHANGE: 20080324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000818686 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-16174 FILM NUMBER: 08706918 BUSINESS ADDRESS: STREET 1: 5 BAZEL ST STREET 2: P O B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 MAIL ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 5 BAZEL ST PO B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 6-K 1 d6k.htm FORM 6-K Form 6-K

 

 

FORM 6-K

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of March 2008

Commission File Number 0-16174

 

 

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Translation of registrant’s name into English)

 

 

5 Basel Street, P.O. Box 3190

Petach Tikva 49131 Israel

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F      X            Form 40-F              

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):             

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):             

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also hereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes                      No      X    

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g(3)-2(b): 82-            

 

 

 


Attached as Exhibit 100 to this Form 6-K are the following materials from the Annual Report on Form 20-F of Teva Pharmaceutical Industries Limited (the “Registrant”) for the year ended December 31, 2007, previously filed on February 29, 2008, formatted in XBRL (Extensible Business Reporting Language): (i) consolidated statements of income for the years ended December 31, 2005, 2006 and 2007; (ii) consolidated balance sheets at December 31, 2006 and 2007; (iii) consolidated statements of changes in shareholders’ equity for the years ended December 31, 2005, 2006 and 2007; (iv) consolidated statements of cash flows for the years ended December 31, 2005, 2006 and 2007; and (v) supplemental as adjusted data for the years ended December 31, 2005, 2006 and 2007.

Users of this data are advised pursuant to Rule 401 of Regulation S-T that the financial and other information contained in the XBRL documents included in this Form 6-K is unaudited and that these are not the official publicly filed financial statements of the Registrant. The purpose of submitting these XBRL formatted documents is to test the related format and technology and, as a result, investors should continue to rely on the official filed version of the furnished documents and not rely on the information in this Form 6-K, including Exhibit 100, in making investment decisions.

In accordance with Rule 402 of Regulation S-T, the information in this Form 6-K, including Exhibit 100, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Registrant)

By:  

/s/ Dan Suesskind

Name:   Dan Suesskind
Title:   Chief Financial Officer

Date: March 24, 2008

EX-100.INS 2 teva-20071231.xml XBRL INSTANCE DOCUMENT 0 1072000000 618000000 681000000 799000000 5250000000 369000000 236000000 1312000000 -4000000 1072000000 2000000 0 1308000000 2480000000 2000000 1.59 2770000000 1.73 0 0 0 310000000 436000000 -7000000 243000000 1072000000 784000000 1276000000 0 2310000000 379000000 157000000 2502000000 134000000 359000000 162000000 -2000000 25000000 27000000 492000000 -538000000 1370000000 -312000000 180000000 -28000000 -105000000 -103000000 422000000 27000000 11000000 96000000 551000000 756000000 805000000 1572000000 8408000000 495000000 155000000 801000000 -95000000 546000000 2000000 1295000000 706000000 4259000000 -3000000 0.69 4149000000 0.72 50000000 48000000 1277000000 390000000 478000000 -89000000 467000000 546000000 1276000000 1332000000 1375000000 4161000000 234000000 65000000 4205000000 180000000 1539000000 229000000 -7000000 37000000 -27000000 56000000 -4058000000 2058000000 2024000000 284000000 32000000 -585000000 112000000 372000000 121000000 3587000000 1987000000 1556000000 152000000 2127000000 795000000 712000000 742000000 0 486000000 830000000 7640000000 11142000000 3398000000 2193000000 387000000 69000000 651000000 5223000000 35000000 544000000 20471000000 9294000000 1879000000 8038000000 4071000000 2458000000 46000000 1332000000 20471000000 7877000000 1386000000 2922000000 0 1956000000 768000000 830000000 1901000000 9408000000 581000000 397000000 2395000000 -42000000 1952000000 1000000 0 2353000000 4877000000 -3000000 2.38 4531000000 2.54 36000000 67000000 0 542000000 316000000 111000000 521000000 1952000000 1332000000 1488000000 0 4520000000 152000000 66000000 5298000000 212000000 37000000 299000000 -1000000 15000000 -16000000 156000000 -1353000000 1813000000 -362000000 197000000 58000000 -129000000 421000000 -117000000 179000000 18000000 1919000000 1733000000 149000000 1914000000 998000000 1387000000 1841000000 326000000 459000000 982000000 9859000000 13724000000 5041000000 2515000000 414000000 80000000 1365000000 4281000000 36000000 632000000 23412000000 9652000000 2440000000 8407000000 5371000000 1433000000 46000000 1488000000 23412000000 8254000000 1383000000 3546000000 7923000000 3057000000 3412000000 2548000000 3226000000 4049000000 -830000000 -596000000 -217000000 3412000000 7923000000 8300000000 3226000000 4049000000 6406000000 -982000000 -830000000 -596000000 63000000 175000000 196000000 -299000000 -229000000 -162000000 25000000 28000000 35000000 134000000 180000000 212000000 -379000000 -234000000 -152000000 -10000000 -26000000 4080000000 546000000 1072000000 1952000000 -51000000 -14000000 -2000000 1000000 2000000 25000000 48000000 67000000 840000000 1078000000 2666000000 6042000000 11142000000 13724000000 -220000000 533000000 740000000 25000000 1072000000 1867000000 1952000000 95000000 -172000000 50000000 1277000000 46000000 2.38 2.3 1.59 Supplemental As Adjusted Income Data The table on the following page presents supplemental data, in U.S. dollar terms, as a percentage of sales and the increase/decrease by item as a percentage of the amount for the comparable period, after taking into account the following items, the exclusion of which management believes facilitates the reader's understanding of the trends in the Company's underlying business: In 2006: - $1,295 million related to a write-off of in-process R+D, which was primarily in connection with the acquisition of Ivax; - $172 million of income resulting from a release of prior years' tax provisions due to closure of tax settlements and the expiration of tax statutes of limitations in various jurisdictions and the tax benefit on certain of the below items; - $95 million in a step-up of Ivax's inventory at its acquisition date; - $50 million for legal costs relating to a settlement with Pfizer Inc. regarding idarubicin, azithromycin and epirubicin; - $36 million of impairment charges, reflecting primarily further impairment of product rights for Purinethol as a result of the increased generic competition for this product. Purinethol product rights were originally obtained in 2003 as part of a litigation settlement with GlaxoSmithKline; - $10 million of restructuring expenses in connection with the Ivax acquisition but relating to Teva's operations; and - $7 million, reflecting a write-off of in-process R+D recorded under "Share in profits (losses) of associated companies". In 2007: Management considers that there were no items appropriate for adjustment in 2007. The data so presented - after these exclusions - are the results used by management and Teva's board of directors to evaluate the operational performance of the Company, to compare against the Company's work plans and budgets, and ultimately to evaluate the performance of management. For example, the Company annually prepares detailed "work plans" for the next three succeeding fiscal years. These are the work plans used to manage the business and are the plans against which management's performance is measured. All of such plans are prepared on a basis comparable to the presentation below, in that none of the plans takes into account those elements that are factored out in the "as adjusted" presentations. In addition, at quarterly meetings of the Board at which management provides financial updates to the Board on the Company's performance, presentations are made comparing the current fiscal quarterly results against: (a) the comparable quarter of the prior year, (b) the immediately preceding fiscal quarter and (c) the work plan. Such presentations are based upon the "as adjusted" approach reflected in the table below. Moreover, while there are always qualitative factors and elements of judgment involved in the granting of annual cash bonuses, the principal quantitative element in the determination of such bonuses are performance targets tied to the work plan, and thus tied to the same "as adjusted" presentation as is set forth below. In arriving at its "as adjusted" presentation, Teva has in the past factored out items, and would expect in the future to continue to factor out items, that either have a non-recurring impact on the income statement or which, in the judgment of Teva's management, are items that, either as a result of their nature or size, Teva would not expect to occur as part of its normal business on a regular basis, and that, were they not singled out, could potentially cause investors to extrapolate future performance from an improper base. While not all inclusive, examples of these items include: purchase accounting adjustments related to acquisitions, including adjustments for write-offs of in-process R+D, and inventory "step-ups" following acquisitions; restructuring charges related to efforts to rationalize and integrate Teva's operations on a global basis; material tax awards or settlements - both in terms of amounts paid or amounts received; impairment charges related to intangible assets such as intellectual property, product rights or goodwill; and the income tax effects of the foregoing types of items when they occur. As adjusted data are non-GAAP financial measures and should not be considered replacements for GAAP results. Teva provides such non-GAAP data on an adjusted basis because management believes that such data provide useful information to investors. However, investors are cautioned that, unlike financial measures prepared in accordance with GAAP, non-GAAP measures may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of acquisition, merger-related, restructuring and other charges, and may not provide a comparable view of the Company's performance to other companies in the pharmaceutical industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. 0000818686 2007-01-01 2007-12-31 0000818686 2005-01-01 2005-12-31 0000818686 2005-12-31 0000818686 2006-12-31 0000818686 2006-01-01 2006-12-31 0000818686 2007-12-31 0000818686 2005-01-01 2005-12-31 0000818686 2005-12-31 0000818686 2005-01-01 2005-12-31 0000818686 2006-01-01 2006-12-31 0000818686 2006-12-31 0000818686 2006-01-01 2006-12-31 0000818686 2006-12-31 0000818686 2007-01-01 2007-12-31 0000818686 2007-12-31 0000818686 2007-01-01 2007-12-31 0000818686 2007-12-31 iso4217:USD pure shares EX-100.SCH 3 teva-20071231.xsd XBRL TAXONOMY EXTENSION SCHEMA link:calculationLink link:presentationLink link:calculationLink link:presentationLink link:calculationLink link:presentationLink link:presentationLink link:calculationLink link:presentationLink link:calculationLink link:presentationLink EX-100.CAL 4 teva-20071231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-100.LAB 5 teva-20071231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-100.PRE 6 teva-20071231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
-----END PRIVACY-ENHANCED MESSAGE-----